Author: Spokane Dermatology Clinic

New Long-Term Data Shows Lebrikizumab Sustains Atopic Dermatitis Clearance With Less Frequent Dosing and Advances Findings from Dr. Philip Werschler of Spokane Dermatology Clinic

June 22, 2026
FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

June 10, 2026

New Long-Term Data Shows Lebrikizumab Sustains Atopic Dermatitis Clearance With Less Frequent Dosing and Advances Findings from Dr. Philip Werschler of Spokane Dermatology Clinic